Time Trends and Income Inequalities in Cancer Incidence and Cancer-Free Life Expectancy - a Cancer Site-Specific Analysis of German Health Insurance Data.

Germany cancer incidence cancer-free life expectancy compression of morbidity income inequalities time trend

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 01 12 2021
accepted: 22 03 2022
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 3 5 2022
Statut: epublish

Résumé

Cancer represents a major burden of morbidity and mortality globally. So far, however, little is known on time trends and inequalities in the lengths of life spent free of any cancer. This study steps into this gap by analyzing time trends and income inequalities in cancer-free life expectancy (CFLE). For this retrospective cohort study, data of a large German health insurer were used (N = 3,405,673individuals, 2006-2018). Income inequalities were assessed using individual income (<60% of German average income (GAI) and ≥60% of GAI). Trends in incidence risks were analysed employing proportional-hazard regression models by splitting the observation time into three periods of 52 months. Trends in CFLE in total and for the most common site-specific cancers were calculated based on multiple decrement life tables. Incidence rates declined in almost all cancers and CFLE increased substantially over time (49.1 (95% CI 48.8-49.4) to 51.9 (95% CI 51.6-52.2) years for men, 53.1 (95% CI 52.7-53.5) to 55.4 (95% CI 55.1-55.8) years for women at age 20 for total cancer) and income groups. Considerable income inequalities in cancer risks were evident in both sexes, but were more pronounced in men (total cancer HR 0.86 (95% CI 0.85-0.87)), with higher-income individuals having lower risks. The highest income inequalities were found in colon (HR 0.90 (95% CI 0.87-0.93)), stomach (HR 0.78 (95% CI 0.73-0.84)), and lung cancer (HR 0.58 (95% CI 0.56-0.60)) in men. A reverse gradient was found for skin (HR 1.39 (95% CI 1.30-1.47) men; HR 1.27 (95% CI 1.20-1.35) women) and prostate cancer (HR 1.13 (95% CI 1.11-1.15)). The proportion of CFLE in total life expectancy declined for lung, skin and cervical cancer in women, indicating a relative shortening of lifetime spent cancer-free. In contrast, increasing proportions were found in breast and prostate cancer. To our knowledge, this is the first study analysing trends and income inequalities in CFLE. The life span free of cancer increased clearly over time. However, not all cancer types contributed equally to this positive development. Income inequalities persisted or tended to widen, which underlines the need for increased public health efforts in socioeconomically vulnerable groups.

Identifiants

pubmed: 35494022
doi: 10.3389/fonc.2022.827028
pmc: PMC9046985
doi:

Types de publication

Journal Article

Langues

eng

Pagination

827028

Informations de copyright

Copyright © 2022 Tetzlaff, Hoebel, Epping, Geyer, Golpon and Tetzlaff.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Dtsch Arztebl Int. 2020 Jul 20;117(29-30):493-499
pubmed: 33087229
Aust N Z J Public Health. 2018 Apr;42(2):180-185
pubmed: 29384240
J Epidemiol Community Health. 2019 Jul;73(7):605-611
pubmed: 30971422
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1906-1913
pubmed: 29633375
PLoS One. 2020 Jan 16;15(1):e0227541
pubmed: 31945102
J Epidemiol Community Health. 2020 Jun;74(7):592-597
pubmed: 32277000
BMC Public Health. 2014 Nov 24;14:1208
pubmed: 25418052
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):858-67
pubmed: 23703507
Br J Cancer. 2021 Mar;124(7):1320-1329
pubmed: 33564123
Public Health. 2018 Jan;154:1-10
pubmed: 29128730
Popul Res Policy Rev. 2017 Jun;36(3):309-330
pubmed: 29056801
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Apr;55(4):448-58
pubmed: 22441514
Cancer Causes Control. 2013 Jun;24(6):1243-55
pubmed: 23580085
Radiol Oncol. 2020 Feb 19;54(1):1-13
pubmed: 32074075
Int J Cancer. 2017 Mar 15;140(6):1306-1316
pubmed: 27925183
Eur J Public Health. 2019 Dec 1;29(6):1118-1124
pubmed: 31329870
Soc Sci Med. 2015 Feb;127:41-50
pubmed: 25037853
BMJ Open. 2015 May 11;5(5):e006588
pubmed: 25967987
BMC Public Health. 2021 Feb 1;21(1):259
pubmed: 33526035
Int J Cancer. 2020 Dec 1;147(11):3029-3036
pubmed: 32449164
Gesundheitswesen. 2010 Jun;72(6):316-22
pubmed: 20480460
Eur J Public Health. 2016 Oct;26(5):804-813
pubmed: 27221607
J Epidemiol Community Health. 2015 May;69(5):432-41
pubmed: 25631857
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
N Engl J Med. 1980 Jul 17;303(3):130-5
pubmed: 7383070
BMC Public Health. 2021 Mar 19;21(1):538
pubmed: 33740928
Gesundheitswesen. 2021 Nov;83(S 02):S77-S86
pubmed: 34695865
Dtsch Arztebl Int. 2021 Mar 5;118(9):137-144
pubmed: 33958031
J Clin Nurs. 2020 Feb;29(3-4):393-415
pubmed: 31713934
SSM Popul Health. 2021 Sep 07;15:100915
pubmed: 34527804
Cancers (Basel). 2021 Jun 05;13(11):
pubmed: 34198798
J Natl Cancer Inst. 2012 Sep 19;104(18):1353-62
pubmed: 22952311
Arch Gynecol Obstet. 2015 Mar;291(3):623-9
pubmed: 25138124
Cancer Epidemiol. 2021 Oct;74:102010
pubmed: 34418667
Environ Health Perspect. 2019 Feb;127(2):24001
pubmed: 30741556
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jul;57(7):869-77
pubmed: 24950836
Int J Environ Res Public Health. 2018 Jan 04;15(1):
pubmed: 29300325
Int J Cancer. 2018 Jan 1;142(1):23-35
pubmed: 28877332
Gesundheitswesen. 2020 Sep;82(8-09):684-690
pubmed: 31311059
Environ Res. 2019 Sep;176:108560
pubmed: 31295664
Br J Cancer. 2017 Oct 24;117(9):1419-1426
pubmed: 28898233
J Epidemiol Community Health. 2017 Jun;71(6):565-575
pubmed: 27682963
BMC Med Res Methodol. 2020 Sep 11;20(1):229
pubmed: 32917135
Front Oncol. 2018 Nov 27;8:536
pubmed: 30542641
Front Oncol. 2018 Sep 25;8:402
pubmed: 30319967
PLoS One. 2020 Nov 20;15(11):e0242433
pubmed: 33216766
BMC Med. 2020 Mar 20;18(1):41
pubmed: 32192480
Br J Cancer. 2015 Mar 31;112 Suppl 1:S116-23
pubmed: 25734390
J Epidemiol Community Health. 2011 Jun;65(6):491-6
pubmed: 21071560

Auteurs

Fabian Tetzlaff (F)

Medical Sociology Unit, Hannover Medical School, Hanover, Germany.

Jens Hoebel (J)

Division of Social Determinants of Health, Robert Koch Institute, Berlin, Germany.

Jelena Epping (J)

Medical Sociology Unit, Hannover Medical School, Hanover, Germany.
Comprehensive Cancer Center Hannover, Hannover Medical School, Hanover, Germany.

Siegfried Geyer (S)

Medical Sociology Unit, Hannover Medical School, Hanover, Germany.
Comprehensive Cancer Center Hannover, Hannover Medical School, Hanover, Germany.

Heiko Golpon (H)

Comprehensive Cancer Center Hannover, Hannover Medical School, Hanover, Germany.
Department of Pneumology, Hannover Medical School, Hanover, Germany.

Juliane Tetzlaff (J)

Medical Sociology Unit, Hannover Medical School, Hanover, Germany.

Classifications MeSH